Free Trial

Baxter International (BAX) Stock Forecast & Price Target

Baxter International logo
$28.71 -0.99 (-3.33%)
Closing price 07/11/2025 03:59 PM Eastern
Extended Trading
$28.74 +0.04 (+0.12%)
As of 07/11/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Baxter International - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
3
Buy
5

Based on 9 Wall Street analysts who have issued ratings for Baxter International in the last 12 months, the stock has a consensus rating of "Hold." Out of the 9 analysts, 1 has given a sell rating, 3 have given a hold rating, and 5 have given a buy rating for BAX.

Consensus Price Target

$36.50
27.13% Upside
According to the 9 analysts' twelve-month price targets for Baxter International, the average price target is $36.50. The highest price target for BAX is $42.00, while the lowest price target for BAX is $28.00. The average price target represents a forecasted upside of 27.13% from the current price of $28.71.
Get the Latest News and Ratings for BAX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Baxter International and its competitors.

Sign Up

BAX Analyst Ratings Over Time

TypeCurrent Forecast
7/12/24 to 7/12/25
1 Month Ago
6/12/24 to 6/12/25
3 Months Ago
4/13/24 to 4/13/25
1 Year Ago
7/13/23 to 7/12/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
3 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
4 Hold rating(s)
9 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$36.50$37.25$38.56$44.38
Forecasted Upside27.13% Upside18.86% Upside38.20% Upside25.66% Upside
Consensus Rating
Hold
Hold
Hold
Hold

BAX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BAX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Baxter International Stock vs. The Competition

TypeBaxter InternationalMedical CompaniesS&P 500
Consensus Rating Score
2.44
2.80
2.54
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside27.13% Upside8,634.01% Upside10.52% Upside
News Sentiment Rating
Neutral News

See Recent BAX News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/9/2025Citigroup
3 of 5 stars
Joanne Wuensch
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral ➝ Neutral$34.00 ➝ $32.00+7.35%
7/8/2025Evercore ISI
2 of 5 stars
Vijay Kumar
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOutperform ➝ Outperform$44.00 ➝ $42.00+41.41%
5/5/2025Morgan Stanley
3 of 5 stars
Patrick Wood
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetUnderweight ➝ Underweight$30.00 ➝ $28.00-8.44%
5/2/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Larry Biegelsen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetEqual Weight ➝ Equal Weight$36.00 ➝ $33.00+7.73%
3/10/2025Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Miksic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$39.00 ➝ $41.00+12.00%
2/26/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
David Roman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold ➝ Buy$42.00+16.66%
2/24/2025Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Hellweg
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy
2/21/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Robbie Marcus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral ➝ Neutral$38.00 ➝ $36.00+7.50%
11/11/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$46.00 ➝ $38.00+11.73%
5/10/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$40.00+11.27%
3/5/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$42.00 ➝ $45.00+2.93%
2/6/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$40.00 ➝ $36.00-8.28%
10/24/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$35.00 ➝ $50.00+52.72%
7/31/2023KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$53.00 ➝ $51.00+8.49%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 11:24 PM ET.


Should I Buy Baxter International Stock? BAX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, July 7, 2025. Please send any questions or comments about these Baxter International pros and cons to contact@marketbeat.com.

Baxter International
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Baxter International Inc.:

  • Baxter International Inc. recently reported earnings per share that exceeded expectations, indicating strong financial performance and potential for growth.
  • The current stock price is around $30.62, which may present a buying opportunity for investors looking for value in the healthcare sector.
  • Analysts have a consensus rating of "Moderate Buy" for Baxter International Inc., suggesting positive sentiment among market experts.
  • The company has shown a revenue increase of 5.4% compared to the same quarter last year, reflecting its ability to grow in a competitive market.
  • Baxter International Inc. has a diversified portfolio across various healthcare segments, which can help mitigate risks associated with market fluctuations.

Baxter International
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Baxter International Inc. for these reasons:

  • The stock has a negative price-to-earnings (P/E) ratio, which may indicate that the company is currently unprofitable or facing challenges in generating earnings.
  • Recent analyst ratings include an "underweight" rating from Morgan Stanley, suggesting that some experts believe the stock may not perform well in the near term.
  • Baxter International Inc. has a relatively high debt-to-equity ratio, which could indicate financial risk if the company faces downturns or increased interest rates.
  • The company has a negative net margin, which means it is currently spending more than it earns, raising concerns about its profitability.
  • One analyst has issued a sell rating, indicating that there are differing opinions on the stock's future performance, which could create uncertainty for investors.

BAX Forecast - Frequently Asked Questions

According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Baxter International is $36.50, with a high forecast of $42.00 and a low forecast of $28.00.

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Baxter International in the last twelve months. There is currently 1 sell rating, 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BAX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BAX, but not buy additional shares or sell existing shares.

According to analysts, Baxter International's stock has a predicted upside of 27.13% based on their 12-month stock forecasts.

Baxter International has been rated by research analysts at Citigroup, Evercore ISI, Morgan Stanley, and Wells Fargo & Company in the past 90 days.

Analysts like Baxter International less than other "medical" companies. The consensus rating for Baxter International is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BAX compares to other companies.


This page (NYSE:BAX) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners